{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Novavax", "query": { "sponsor": "Novavax" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Novavax&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-18T22:55:31.168Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05973006", "title": "Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine", "type": "BIOLOGICAL" }, { "name": "Prototype/XBB.1.5 Bivalent Vaccine (5 µg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "11 Years to 18 Years" }, "enrollment_count": 400, "start_date": "2023-08-16", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 20, "location_summary": "Davie, Florida • Jacksonville, Florida • Miami, Florida + 17 more", "locations": [ { "city": "Davie", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "River Forest", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973006" }, { "nct_id": "NCT00754455", "title": "Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza VLP Vaccine (recombinant)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 317, "start_date": "2008-09", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-07-18", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 4, "location_summary": "Pembroke Pines, Florida • Kansas City, Missouri • Warwick, Rhode Island + 1 more", "locations": [ { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Warwick", "state": "Rhode Island" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754455" }, { "nct_id": "NCT06409663", "title": "A Strain Change Study for SARS-CoV-2 rS Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Acute Respiratory Syndrome Coronavirus 2 Infection" ], "interventions": [ { "name": "NVX-CoV2705 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 60, "start_date": "2024-10-14", "completion_date": "2025-04-17", "has_results": false, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 2, "location_summary": "Phoenix, Arizona • Austin, Texas", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06409663" }, { "nct_id": "NCT02608502", "title": "A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus (RSV)" ], "interventions": [ { "name": "RSV-F Vaccine", "type": "BIOLOGICAL" }, { "name": "Phosphate Buffer Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 11850, "start_date": "2015-11", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608502" }, { "nct_id": "NCT07079670", "title": "Safety and Immunogenicity of NVX-CoV2705", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "SARS-CoV-2 Infection" ], "interventions": [ { "name": "NVX-CoV2705", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "12 Years to 90 Years" }, "enrollment_count": 676, "start_date": "2025-10-09", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Melrose Park", "state": "Illinois" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07079670" }, { "nct_id": "NCT02078674", "title": "A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Influenza (Pandemic)" ], "interventions": [ { "name": "Monovalent Avian Influenza VLP (H7N9)", "type": "BIOLOGICAL" }, { "name": "Matrix-M1™ adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 610, "start_date": "2014-03", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-09-23", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 5, "location_summary": "Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more", "locations": [ { "city": "Walnut Creek", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Endwell", "state": "New York" }, { "city": "Mt. Pleasant", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02078674" }, { "nct_id": "NCT07086222", "title": "Efficacy and Safety of NVX-CoV2705", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COVID-19", "Sars-CoV-2 Infection" ], "interventions": [ { "name": "NVX-CoV2705", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "50 Years to 65 Years" }, "enrollment_count": 6500, "start_date": "2025-11-20", "completion_date": "2026-11-18", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 99, "location_summary": "Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gadsden", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07086222" }, { "nct_id": "NCT01709019", "title": "RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus (RSV)" ], "interventions": [ { "name": "Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)", "type": "BIOLOGICAL" }, { "name": "Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)", "type": "BIOLOGICAL" }, { "name": "High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)", "type": "BIOLOGICAL" }, { "name": "High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)", "type": "BIOLOGICAL" }, { "name": "Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 220, "start_date": "2012-10", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 4, "location_summary": "Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709019" }, { "nct_id": "NCT00519389", "title": "Safety, Reactogenicity and Immunogenicity of an H5N1 VLP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pandemic Influenza" ], "interventions": [ { "name": "H5N1 VLP Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 230, "start_date": "2007-07", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00519389" }, { "nct_id": "NCT03658629", "title": "Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "NanoFlu (Quad-NIV)", "type": "BIOLOGICAL" }, { "name": "Matrix-M Adjuvant", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Fluzone HD", "type": "BIOLOGICAL" }, { "name": "Flublok Quadrivalent", "type": "BIOLOGICAL" }, { "name": "Influenza Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1375, "start_date": "2018-09-24", "completion_date": "2019-04-26", "has_results": true, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-09-18T22:55:31.168Z", "location_count": 14, "location_summary": "Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Stockbridge", "state": "Georgia" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Norfolk", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03658629" } ] }